The most domestically selling meningococcemia vaccine, ‘Menveo’ to make a fresh start in GSK

Published: 2015-09-17 15:23:30

Updated: 2015-09-17 16:07:46

The most famous traditional vaccine company, GSK(GlaxoSmithKline), acquired product approval for ‘Menveo,’ the most domestically selling meningococcemia vaccine, from the 31^st of August.

This is execution of the agreement for GSK to take over the Novartis’s vaccine department on April 2014; therefore, GSK has now established a more stable vaccine portfolio.

‘Menveo’ is a tetravalent meningoco...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.

The most domestically selling meningococcemia vaccine, ‘Menveo’ to make a fresh start in GSK

The most famous traditional vaccine company, GSK(GlaxoSmithKline), acquired product approval for ‘Menveo,’ the most domestically selling meningococcemia vaccine, from the 31st of August.

Fees

The most famous traditional vaccine company, GSK(GlaxoSmithKline), acquired product approval for ‘Menveo,’ the most domestically selling meningococcemia vaccine, from the 31^st of August.